day 2: track 2, patient’s role, dave leventhal (pfizer) jane larkindale, jeffrey sherman,
Published 8 years ago • 183 plays • Length 41:39Download video MP4
Download video MP3
Similar videos
-
19:19
let's get vascular: part ii
-
3:08:36
evm virtual interactive: day 2 - various
-
1:54
diagnosing type 2 diabetes
-
7:36
introducing remission - type 2 diabetes
-
1:46
a4m 30th annual spring congress: module v with james lavalle, rph
-
1:12
vascular medicine: a companion to braunwald's heart disease, 2nd edition
-
0:31
adrenalin ver2
-
2:25
a phase ii adaptive study of dasatinib and inotuzumab-based induction for newly diagnosed ph all
-
0:53
glp-1 agonists and sglt-2 inhibitors for treating adults with scd and nephropathy
-
2:43
24-hour urine testing does not add value to multiple myeloma response assessments
-
2:28
machine learning derived three-parameter prognostic model for survival in patients with bpdcn
-
4:43
an individualized sequential allosct approach in patients with r/r aml or hr-mds with active disease
-
2:59
latest clinical needs across neurological disorders.
-
2:37
the importance of secondary cancer screening programs in hodgkin lymphoma survivors
-
3:08
current driving restrictions after week 4 post-car t-cell therapy appear unnecessary
-
0:47
cll highlights from ash: the phase iii amplify trial
-
3:04
the logistical challenges of car t-cell therapy in non-hodgkin lymphoma
-
3:20
the management of patients with r/r aml who develop resistance to idh inhibitors
-
14:50
the hope of cancer treatment: insights from dr. david agus